|
|
850 Maude Avenue
Mountain View, CA 94043 USA
phone:650-632-2900
fax:650-632-2910
|
|
| Symbol |
private |
| Exchange |
|
| Founded |
1997 |
| Employees |
|
|
|
| www.chemocentryx.com
|
|
| Research Sector |
Biotech Specialty Pharma |
|
 |
| Summary Description |
| Chemokine-based therapies for inflammatory disorders, cancer, autoimmune and infectious diseases. |
|
| Management |
| Thomas J. Schall, Ph.D., President and CEO; Markus J. Cappel, Ph.D., Chief Business Officer; Susan M. Kanaya, Senior Vice President, Finance and Chief Financial Officer; Juan Jaen, Ph.D., Senior Vice President, Drug Discovery; Petrus (Pirow) Bekker, M.D., Ph.D., Senior Vice President, Medical & Clinical Affairs |
| |
|
|
| |
|
| Keywords |
| chemokine, therapeutics, chemoattractant, inflammatory, pharmacokinetics, Type 2 Diabetes, rhumatoid arthritis, cancer, crohn's disease, drug discovery |
|
|
|
| Description |
|
ChemoCentryx, Inc. discovers, develops and commercializes new medicines for inflammatory disorders, cancer, autoimmune and infectious diseases by targeting the chemokine system, the master regulator of immune function. |
|
| Products / Services |
The company's lead drug candidate, Traficet-EN? (CCX282), targets the CCR9 chemokine receptor. It recently completed a Phase II/III clinical trial for the treatment of patients with moderate-to-severe Crohn's disease.
Another investigational new drug in clinical trials is CCX025 which is the second orally administered compound that inhibits the CCR9 chemokine receptor. CCX140, which targets the CCR2 chemokine receptor, recently began a Phase II trial in Type 2 diabetes. CCX354, a CCR1 antagonist, started a Phase II study in rheumatoid arthritis in December 2009. CCX168, a C5aR antagonist, began a Phase I clinical trial in January 2010. CCX832, a ChemR23 antagonist, is in the late stages of preclinical development and is expected to advance into Phase I studies in late 2010. The company plans to target cancer, autoimmune, and inflammatory disorders.
|
|
| Technology / Differentiation |
| The company's portfolio focuses primarily on small molecule therapeutics that target the chemokine network to modulate the inflammatory response. The EnabaLink? technology suite is specifically designed to unlock the chemokine system's complexity and to accelerate a productive drug discovery program. ChemoCentryx's proprietary EnabaLink drug discovery technologies allow scientists to accurately predict the specific chemokine receptors implicated in a given condition and to identify and optimize small molecule compounds best suited for treatment of the disease. |
|
|
|
|
|
|
|
|
Biotech & Specialty Pharma
Healthcare Services
Medical Devices & Tech
OneMedPlace Member
AdvaMed Members